Update on Maryland facilities that received products from the New England Compounding Center (NECC)

October 15, 2012

In late September, the New England Compounding Center (NECC) recalled three lots of methylprednisolone as a result of an outbreak of fungal meningitis associated with this product.  These three implicated lots had been distributed to seven Maryland facilities.  Each of these seven facilities is working closely with the Department to notify all recipients and ask them to be vigilant for signs and symptoms of meningitis and other infections.  The list of the seven facilities that received the implicated lots is available here.

On October 4, 2012, NECC expanded its recall to include additional medications that could be injected into the cerebrospinal fluid or the eye.  No illnesses have definitively been associated with these additional medications. Twenty-five facilities in Maryland received these injectable medications from NECC.  All 25 facilities are cooperating with the Department in the recall and have stopped using the NECC products.  The list of the 25 facilities that received the recalled lots of injectable products is available here.

Subsequent to the recall on October 4, NECC recalled all of its products, including products not made for injection. On October 15, 2012, FDA issued a MedWatch notice related to NECC products, entitled "FDA Statement on Fungal Meningitis Outbreak: Additional Patient Notification Advised". That notice is available here.